Reynoso Jamie L. sold $36K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 7,289 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.91 on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jun 11, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides transparency on executive share activity but does not introduce new operational, regulatory, or financial information about the company.

02

Market read

A routine, pre-arranged insider sale is disclosed; it may slightly influence sentiment but is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

Traders may over-weight small insider sales; the more relevant signal would be large, non-10b5-1 transactions or changes in guidance/regulatory outcomes.

Relevance 2/10Novelty 2/10Timing: Filed 2026-06-11 (same day as the sale)

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. (DE).

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Jamie L. Reynoso sold 7,289 shares in an open-market transaction on 2026-06-11 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven rather than directional.

Evidence & confidence

The filing is a routine insider sale (10b5-1 pre-arranged) with modest dollar value (~$36K), providing disclosure but not new company fundamentals.

Market effects

No direct sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish information.

Key entities

  • CLOVER HEALTH INVESTMENTS, CORP. /DE

    Company whose shares were sold by an officer under a 10b5-1 plan.

  • Reynoso Jamie L.

    CEO, Medicare Advantage; sold 7,289 shares on 2026-06-11.

  • 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive weight of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.